Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated [Flag] Directors [Member] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Consolidation Items [Axis] Consolidation Items [Domain] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Additional paid-in capital Additional Paid in Capital Stock-based compensation expense Restricted Stock or Unit Expense Depreciation expense Depreciation Issuance of shares in consulting agreements Condensed Consolidated Balance Sheets [Abstract] Net loss per share, basic (in dollars per share) Amortization of debt discount Amortization of debt discount Cash and cash equivalents Cash Equivalents and Concentration of Cash Balance Cash and Cash Equivalents, Policy [Policy Text Block] Cash paid for interest Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Changes in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Commitments and Contingencies Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock shares outstanding (in shares) Common stock, $0.00033 par value, 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 55,921,806 and 54,878,233 issued and outstanding at June 30, 2026 and December 31, 2025, respectively Comprehensive loss Current income tax expense Total current liabilities Liabilities, Current Current liabilities: Venture Loan and Security Agreement Debt Disclosure [Text Block] Face amount Face amount Interest rate Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Name [Domain] Unamortized debt discount Debt Instrument, Unamortized Discount Venture Loan and Security Agreement [Abstract] Convertible Debentures [Abstract] Debt Instrument [Axis] Debt Instrument [Line Items] Schedule of Long-Term Debt Instruments [Table] Net loss per share, diluted (in dollars per share) Federal statutory income tax rate Stock-based compensation expense Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock Options [Abstract] Share-Based Payment Arrangement, Additional Disclosure [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Stock-Based Compensation [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Interest expense associated with extinguishment of debt Loss on retirement of debt Interest expense associated with extinguishment of debt Gain (Loss) on Extinguishment of Debt General and administrative expenses General and Administrative Expense General and Administrative [Member] Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract] Accrued interest and penalties Income Taxes Income Taxes Income Tax, Policy [Policy Text Block] Interest expense Interest Expense, Debt Salaries and benefits Labor and Related Expense Total liabilities Liabilities LIABILITIES Liabilities [Abstract] Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Related and Nonrelated Parties [Axis] Net cash (used)/provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Net loss Net loss Interest income (expenses), net Nonoperating Income (Expense) [Abstract] Noncurrent assets: Assets, Noncurrent [Abstract] Noncurrent liabilities: Liabilities, Noncurrent [Abstract] Professional fees Professional Fees Promissory Note [Abstract] Loss from operations Operating Income (Loss) General administrative expenses Other General and Administrative Expense Retirement Plan Prepaid expenses Proceeds from issuance Proceeds from issuance Proceeds from issuance of common stock, net of issuance costs Proceeds from issuance of common stock Proceeds from issuance of warrants Proceeds from issuance of secured loans Proceeds from Issuance of Secured Debt Property and equipment, net Property, Plant and Equipment, Net Related and Nonrelated Parties [Domain] Loan principal payment Repayments of Secured Debt Research and Development Research and Development Expense, Policy [Policy Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Sale of Stock [Domain] Aggregate number of shares purchased in securities offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Offering price per share (in dollars per share) Sale of Stock, Price Per Share Net proceeds from securities offering Sale of Stock, Consideration Received on Transaction Stock-Based Compensation Expense Current portion of debt Secured Debt, Current Debt, net of debt discount Segment Reporting Segment Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Segment Reporting Information [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Granted restricted stock units (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Options outstanding, ending balance (in shares) Options outstanding, beginning balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options outstanding, ending balance (in dollars per share) Options outstanding, beginning balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Equity Award [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Condensed Consolidated Statements of Cash Flows [Abstract] Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY Number of shares of common stock that can be called by warrants (in shares) Number of shares of common stock that can be called by warrants (in shares) Sale of Stock [Axis] Supplemental information of cash and non-cash transactions: Total current assets Assets, Current Current assets: Assets, Current [Abstract] Unrecognized tax benefits Warrants to Purchase Common Stock [Member] Warrant [Member] Weighted average common shares outstanding, diluted (in shares) Weighted average common shares outstanding, basic (in shares) Common Stock [Member] Research and development expenses Research and Development Expense Total assets Assets Interest income Investment Income, Interest Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Segment Expenses [Abstract] Segment Reporting Information, Profit (Loss) [Abstract] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Statement [Table] Antidilutive Securities, Name [Domain] Promissory Note [Abstract] Convertible Debentures [Abstract] Long-Term Debt, by Current and Noncurrent [Abstract] ASSETS Assets [Abstract] Statement [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Quoted Prices in Active Markets (Level 1) [Member] Quoted Prices in Inactive Markets (Level 2) [Member] Significant Unobservable Inputs (Level 3) [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Issuance of warrants Adjustments to Additional Paid in Capital, Warrant Issued Operating expenses: Operating Expenses [Abstract] Total operating expenses Operating Expenses Antidilutive impact to EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Per share information: Antidilutive Securities Antidilutive Security, Excluded EPS Calculation [Table] Net Loss per Common Share Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share [Abstract] Earnings Per Share, Diluted, Other Disclosure [Abstract] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Common stock, par value (in dollars per share) Common stock, par value Total stockholders' equity Balance Balance Equity, Attributable to Parent Income tax benefit due to realization uncertainties Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Benefit from income taxes Benefit from income taxes Income Tax Expense (Benefit) Equity Components [Axis] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Equity Component [Domain] Stock Options [Member] Stock Options to Purchase Common Stock [Member] Employee Stock Option [Member] Forfeited and expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Forfeited and expired (in dollars per share) Convertible Debentures Patent Costs Selling, General and Administrative Expenses, Policy [Policy Text Block] Issuances of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Issuances of common stock, net of issuance costs (in shares) Issuance of common stock (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Segments [Axis] Number of Shares [Roll Forward] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Liquidity [Abstract] Business Combination, Consideration Transferred [Abstract] Leases [Abstract] Commitments and contingencies (Note 9) Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Nature of Operations Accounts payable Accrued expenses Total Accrued Liabilities, Current Accrued professional fees Accrued Professional Fees, Current Accrued rent Accrued interest on debt Accrued compensation Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Segments [Domain] Reconciling Item [Member] Operating Segment [Member] Fair Value Hierarchy and NAV [Domain] Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net proceeds from issuance of debt Proceeds from exercise of pre-funded warrants Summary of Significant Accounting Policies Interest income (expenses), net Interest Income (Expense), Nonoperating Accrued Expenses [Abstract] Nature of Operations [Abstract] Balance (in shares) Balance (in shares) Shares, Outstanding Loan repayment Loan repayment Repayments of Debt Fair Value Hierarchy and NAV [Axis] Accrued Expenses Commitments and Contingencies [Abstract] Income Taxes [Abstract] Fair Value of Financial Instruments [Abstract] Venture Loan and Security Agreement [Abstract] Retirement Plan [Abstract] Stock Option Activity Stock-Based Compensation [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Research and Development [Member] Summary of Significant Accounting Policies [Abstract] Segment Reporting [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Unaudited Interim Financial Statements 401(k) employer contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Unamortized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Weighted Average Exercise Price [Roll Forward] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Performance-Based Restricted Stock Units [Member] Performance-Based Restricted Stock Units [Member] Unamortized Stock Compensation Expense [Abstract] Plan Name [Axis] Plan Name [Domain] Award Type [Axis] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Additional shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Issuance of common stock for consulting agreement Issuance of common stock for consulting agreement (in shares) Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of operating segments Number of Operating Segments Number of reportable segments Number of Reportable Segments Fair Value of Financial Instruments [Abstract] Fair Value, Net Asset (Liability) [Abstract] Other Commitments [Table] Other Commitments [Axis] Other Commitments [Domain] Other Commitments [Line Items] Commitments and Contingencies [Abstract] Other Commitments [Abstract] Term of option Redemption price percentage Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Rent expense Future Payments for Finance Lease Liabilities [Abstract] Supplemental Cash Flow Information Related to Finance Lease [Abstract] Financing lease right-to-use assets Finance lease liability capitalized interest rate Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Financing Lease [Abstract] Lessee, Finance Lease, Description [Abstract] Net increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash and cash equivalents at beginning of period Cash and cash equivalents at the end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Payments of finance lease obligations Finance Lease, Principal Payments Finance lease depreciation expense Finance Lease, Right-of-Use Asset, Amortization Remaining lease liability Finance Lease, Liability Financing lease obligation-short term Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Financing lease obligation-long term Total future minimum lease payments Finance Lease, Liability, to be Paid 2026 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Future Payments for Financing Lease Liability Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Leases Lessee, Finance Leases [Text Block] Leases Leases Lessee, Operating Leases [Text Block] Term of financing lease Term of warrants Warrants and Rights Outstanding, Term Interest expense Interest expense Interest Expense, Nonoperating Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding License agreements with each of the Company's executives that generally provide for product. Merck KGaA License Agreement [Member] Merck KGaA License Agreement [Member] Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Term of Royalty Payment Term of royalty payment Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement. Milestone payments, Achievement of Certain Aggregate Sales Levels Milestone payments for aggregate sales levels of product Royalty percentage paid on net sales of the product detailed in the license agreement. Royalty Percentage Paid on Net Sales of Product Royalty percentage paid on net sales of product Payments to be made for development and first commercial sale milestones detailed in the license agreement. Milestone payments, Development and first commercial sales Milestone payments for development and first commercial sales Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities. Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block] Supplemental Cash Flow Information Related to Financing Lease Liquidity and Capital Resources [Abstract] The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern. Liquidity and Capital Resources [Text Block] Liquidity and Capital Resources The entire disclosure for promissory notes. Promissory Note [Text Block] Promissory Note The cash inflow from issuance of pre-funded warrants with rights to purchase common shares at predetermined price. Proceeds from Issuance of Pre-funded Warrants Proceeds from issuance of pre-funded warrants The cash inflow from the additional capital contribution to the entity in connection with and At-The-Market program. Proceeds from Issuance of Common Stock, At-The-Market Program Proceeds from issuance of common stock from at-the-market program, net of issuance costs Net proceeds from issuance of common stock from at-the-market program Amount of current income tax expense (benefit) from the sale of unused NOL carryforwards to other New Jersey-based corporate taxpayers, net of transaction costs, in accordance with the State of New Jersey's Technology Business Tax Certificate Transfer (NOL) Program. Income Tax Expense (Benefit) from Sale of New Jersey Unused Net Operating Loss Carryforwards Income tax benefit from sale of New Jersey NOL carryforwards The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date. Liability for Uncertain Tax Positions Uncertain tax positions Statutory lifetime cap on total cumulative value of unused NOL carryforwards sold to other New Jersey-based corporate taxpayers in accordance with the State of New Jersey's Technology Business Tax Certificate Transfer (NOL) Program. Statutory Lifetime Cap on New Jersey Unused Net Operating Loss Carryforwards Lifetime cap on New Jersey NOL carryforwards sold Disclosure of accounting policy for significant risks and uncertainties. Significant Risks and Uncertainties, Policy [Policy Text Block] Significant Risks and Uncertainties Disclosure of accounting policy for convertible debentures and embedded derivatives. Convertible Debentures, Embedded Derivatives [Policy Text Block] Convertible Debentures and Embedded Derivative Evaluation Disclosure of accounting policy for common stock warrants. Warrants, Policy [Policy Text Block] Warrants to Acquire Common Stock The amount of estimated aggregate monthly rental expense under finance lease. Lessee, Finance Lease, Monthly Rental Expense Aggregate monthly rental payments The number of finance leases entered into by the lessee during the period. Lessee, Finance Lease, Number of Leases Number of financing leases entered into Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in first fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finance Lease, Liability to be Paid, Year One and Thereafter 2027 and after Amount of cash outflow for principal and interest payments on finance lease. Finance Lease, Principal and Interest Payments Cash paid for finance lease liabilities Amount of lease cost recognized by lessee for finance lease contract. Finance Lease, Cost Total cost of financing leases Amount of expense for research and development classified as other. Research and Development Expense, Other Other development expenses Single business segment for developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy. PDS [Member] PDS [Member] Amount of expense associated with the process of bringing a new drug or medical device to market, including preclinical research, clinical trials, and regulatory submissions. Research and Development Expense, Clinical Clinical development expenses On April 30, 2026, the Company entered into a Securities Purchase Agreement to sell to YA II PN, LTD., a Cayman Islands exempt limited company (the "Investor") and the Investor agreed to purchase from the Company a promissory note (the "Promissory Note") in an aggregate principal amount of $6,000,000. Promissory Note [Member] Promissory Note [Member] Securities Purchase Agreement (the "April 2026 Securities Purchase Agreement") entered into on April 30, 2026 with YA II PN, LTD., a Cayman Islands exempt limited company. April 2026 Securities Purchase Agreement [ [Member] April 2026 Securities Purchase Agreement [ [Member] The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination, and from the issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).. Proceeds from Debt and Issuance of Warrants Gross proceeds On August 24, 2022, the Company, as borrower (the "Borrower"), entered into a Venture Loan and Security Agreement (the "Loan and Security Agreement") by and among Borrower, PDS Operating Corporation, as guarantor ("Guarantor", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the "Loan Parties" and each individually a "Loan Party") , the persons party thereto from time to time as lenders (collectively, the "Lenders"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the "Collateral Agent"). The Loan and Security Agreement provides for six separate and independent term loans. Term Loans [Member] Loan and Security Agreement [Member] Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options. Percentage of Common Stock outstanding Percentage of Common Stock outstanding used to determine annual increase in the plan limit Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans). Equity Compensation Plans [Member] The Plans [Member] In 2018, the Company's stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards. Equity Incentive Plan 2018 [Member] 2018 Equity Incentive Plan [Member] In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units ("RSUs"), subject to increases. Equity Incentive Plan 2014 [Member] 2014 Equity Incentive Plan [Member] The 2019 Inducement Plan provides for the grant of non-qualified stock options. Inducement Plan 2019 [Member] 2019 Inducement Plan [Member] Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers. Proceeds from Sale of Unused Net Operating Loss Carryforwards Proceeds from sale of tax benefits Number of shares of common stock the Company agreed to sell together with pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant (the February 2025 Offering) pursuant to a Securities Purchase Agreement entered into with certain purchasers in February 2025. Securities Purchase Agreement, Shares to be Sold, Shares Aggregate shares to be sold (in shares) The number of directors participating in the Securities Purchase Offering. Number of Directors Participating in Securities Purchase Offering Number of directors participating in securities offering Cash received on stock transaction before deduction of issuance costs. Sale of Stock, Gross Consideration Received on Transaction Gross proceeds from securities offering Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals. Commission Percentage Commission paid on Placement Shares sold The combined purchase price per share and warrant. Combined Purchase Price Per Share and Warrant Combined purchase price per share and warrant (in dollars per share) The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals. Placement Shares, Available for future sale Placement Shares available for sale Number of New Jersey corporations purchasing tax benefits pursuant to the Company's participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2023. Number of Corporations purchasing tax benefits Number of New Jersey corporations purchasing tax benefits Common stock warrants that give the holder the right to purchase shares of common stock in accordance with the terms of a Securities Purchase Agreement. Common Stock Warrants [Member] Common Stock Warrants [Member] Prefunded warrants that give the holder the right to purchase shares of common stock in accordance with the terms of a Securities Purchase Agreement. Pre-funded Warrants [Member] Pre-funded Warrants [Member] On June 15, 2026, the Company entered into a Sales Agreement (the "June 2026 Sales Agreement") with Yorkville Securities, LLC, an affiliate of the Investor ("Yorkville Securities"), and B. Riley Securities, Inc. ("B. Riley Securities," each of Yorkville Securities and B. Riley Securities individually an "Agent" and collectively, the "Agents"), with respect to an "at-the-market" offering program. June 2026 Sales Agreement [Member] June 2026 Sales Agreement [Member] In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals. In August 2024, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement entered into in August 2022. The New Sales Agreement superseded and replaced the Sales Agreement. Sales Agreement and New Sales Agreement [Member] Sales Agreement and New Sales Agreement [Member] In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals. At Market Issuance Sales Agreement [Member] Sales Agreement [Member] In August 2024, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement entered into in August 2022. The New Sales Agreement superseded and replaced the Sales Agreement. Amended and Restated At Market Issuance Sales Agreement [Member] New Sales Agreement [Member] Securities Purchase Agreement entered into with certain purchasers in February 2025, pursuant to which the Company agreed to sell pre-funded warrants and common stock warrants to purchase shares of common stock (the February 2025 Offering). February 2025 Offering [Member] February 2025 Offering [Member] Securities Purchase Agreement entered into with certain purchasers in November 2025, pursuant to which the Company agreed to sell common stock as well as pre-funded warrants and common stock warrants to purchase shares of common stock (the November 2025 Offering). November 2025 Offering [Member] November 2025 Offering [Member] Securities Purchase Agreement (the "Purchase Agreement") entered into on April 30, 2025 with certain third party lenders and JGB Collateral LLC, as collateral agent, pursuant to which the Company agreed to sell senior secured convertible debentures and warrants to purchase shares of common stock. Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] On April 30, 2025, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain third party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures and (ii) warrants to purchase shares of common stock. Senior Secured Convertible Debentures [Member] Debentures [Member] Number of new stock issued during the period pursuant to an at-the-market program. Stock Issued During Period, Shares, New Issues, At-The-Market Program Issuance of common stock from at-the-market program (in shares) Issuance of common stock from at-the-market program, net (in shares) Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Adjustments to Additional Paid in Capital, Pre-Funded Warrants Issued Issuance of pre-funded warrants Equity impact of the value of new stock issued during the period pursuant to an at-the-market program. Stock Issued During Period, Value, New Issues, At-The-Market Program Issuance of common stock from at-the-market program, net Value of stock issued as a result of the exercise of pre-funded warrants. Stock Issued During Period, Value, Exercise of Pre-Funded Warrants Exercise of pre-funded warrants Number of shares issued during the period as a result of the exercise of pre-funded warrants. Stock Issued During Period, Shares, Exercise of Pre-Funded Warrants Exercise of pre-funded warrants (in shares) Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research and Development Costs, Current Accrued research and development